- Home
- WGRX vs BEAT Comparison
WGRX vs BEAT Comparison
Compare WGRX & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- BEAT
- Stock Information
- Founded
- WGRX 2022
- BEAT 2015
- Country
- WGRX United States
- BEAT United States
- Employees
- WGRX N/A
- BEAT N/A
- Industry
- WGRX Other Pharmaceuticals
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- WGRX Health Care
- BEAT Technology
- Exchange
- WGRX Nasdaq
- BEAT Nasdaq
- Market Cap
- WGRX 60.2M
- BEAT 63.5M
- IPO Year
- WGRX 2025
- BEAT 2021
- Fundamental
- Price
- WGRX $0.55
- BEAT $0.59
- Analyst Decision
- WGRX
- BEAT
- Analyst Count
- WGRX 0
- BEAT 0
- Target Price
- WGRX N/A
- BEAT N/A
- AVG Volume (30 Days)
- WGRX 2.3M
- BEAT 698.9K
- Earning Date
- WGRX 11-19-2025
- BEAT 11-13-2025
- Dividend Yield
- WGRX N/A
- BEAT N/A
- EPS Growth
- WGRX N/A
- BEAT N/A
- EPS
- WGRX N/A
- BEAT N/A
- Revenue
- WGRX $34,077,635.00
- BEAT N/A
- Revenue This Year
- WGRX N/A
- BEAT N/A
- Revenue Next Year
- WGRX N/A
- BEAT $28.23
- P/E Ratio
- WGRX N/A
- BEAT N/A
- Revenue Growth
- WGRX 495.93
- BEAT N/A
- 52 Week Low
- WGRX $0.34
- BEAT $0.54
- 52 Week High
- WGRX $7.04
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- WGRX 46.02
- BEAT 19.81
- Support Level
- WGRX $0.44
- BEAT $0.54
- Resistance Level
- WGRX $0.71
- BEAT $1.80
- Average True Range (ATR)
- WGRX 0.07
- BEAT 0.19
- MACD
- WGRX 0.00
- BEAT -0.12
- Stochastic Oscillator
- WGRX 44.15
- BEAT 3.99
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.